India, June 18 -- Shares of Scholar Rock Holding Corporation (SRRK) gained over 15% on Wednesday morning after the late-stage biopharmaceutical company announced positive results from the Phase 2 trial assessing apitegromab in combination with tirzepatide to preserve lean mass during tirzepatide-induced weight loss.
SRRK is currently trading at $35.95, up $4.80 or 15.38%, on the Nasdaq. The stock opened its trading at $33.50 after closing Tuesday at $31.15. The stock has traded between $6.76 and $46.98 in the past 52-week period.
The trial demonstrated that 30% of total weight loss with tirzepatide alone was due to lean mass loss. Apitegromab therapy (10 mg/kg) with tirzepatide preserved an additional 4.2 pounds (1.9 kilograms) or 54.9% o...